The conversation is moving beyond the “miracle” of weight‑loss drugs (OZEMPIC, MOUNJARO). A major new BMJ meta‑analysis (West et al., 2026) shows that when people stop GLP‑1 medications, weight – and cardiometabolic risk – comes back quickly, sometimes within a year. Dr Mosima Mabunda, Chief Clinical Officer at Vitality, chats to Leigh-Anne Williams about how obesity treatment isn’t just an injection – it’s a programme grounded in behavioural science, clinical support, and long-term health.